Eytan M. Stein
艾顿·斯坦
MD
Associate Attending Physician, Leukemia Service; Director, Program for Drug Development in Leukemia白血病科副主治医师，白血病药物开发项目主任
👥Biography 个人简介
Dr. Eytan Stein is the leading clinical investigator for IDH-mutated AML, having led pivotal trials of enasidenib (IDH2) and ivosidenib (IDH1). His translational research uncovering differentiation syndrome and resistance mechanisms to IDH inhibitors has directly improved patient management and informed next-generation drug design.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IDH Inhibitor Clinical Development
Spearheaded phase I/II and pivotal trials for enasidenib and ivosidenib, demonstrating that IDH inhibition induces leukemic differentiation and achieves complete remissions in IDH-mutated relapsed/refractory AML.
Differentiation Syndrome Management
Characterized the clinical features, incidence, and management of IDH inhibitor-associated differentiation syndrome, publishing guidelines that reduced morbidity and treatment discontinuation.
Representative Works 代表性著作
Enasidenib in Mutant-IDH2 Relapsed/Refractory AML
Blood (2017)
First-in-human trial of enasidenib establishing proof of concept for IDH2 inhibition in AML, leading to FDA breakthrough therapy designation and approval.
Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Journal of Clinical Oncology (2019)
Phase I trial demonstrating ivosidenib induces complete remissions in IDH1-mutated AML, supporting FDA approval of the first IDH1 inhibitor.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 艾顿·斯坦 的研究动态
Follow Eytan M. Stein's research updates
留下邮箱，当我们发布与 Eytan M. Stein（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment